Table 2.

Dupilumab effectiveness at Weeks 16 and 32 by sex, baseline body mass index (< 25 and ≥ 25) and baseline Eczema Area and Severity Index (< 30 and ≥ 30).

EASI reduction	All patients (n = 9)	Sex		Baseline BMI		Baseline EASI
		Male (n = 4)	Female (n = 5)	BMI < 5 (n = 5)	BMI ≥ 25 (n = 4)	EASI < 30 (n = 3)	EASI ≥ 30 (n = 6)
Week 16, n (%)
EASI75	9 (100)	4 (100)	5 (100)	5 (100)	4 (100)	3 (100)	6 (100)
EASI90	4 (44.4)	1 (25.0)	3 (60.0)	3 (60.0)	1 (25.0)	1 (33.3)	3 (50.0)
EASI100	2 (22.2)	0	2 (40.0)	1 (20.0)	0	1 (33.3)	1 (16.7)
Week 32, n (%)
EASI75	9 (100)	4 (100)	5 (100)	5 (100)	4 (100)	3 (100)	6 (100)
EASI90	4 (44.4)	2 (50.0)	2 (40.0)	4 (80.0)	0	1 (33.3)	3 (50.0)
EASI100	2 (22.2)	0	2 (40.0)	2 (40.0)	0	1 (33.3)	1 (16.7)

BMI, body mass index; EASI, Eczema Area and Severity Index.